Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News bluebird bio Inc BLUE

Healthcare Biotechnology
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new... see more

Recent & Breaking News (NDAQ:BLUE)

bluebird bio Sells Second Priority Review Voucher for $95 Million

Business Wire January 6, 2023

bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

Business Wire January 5, 2023

bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer

Business Wire January 3, 2023

FDA Lifts Partial Clinical Hold for bluebird bio's Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18

Business Wire December 19, 2022

New Data from bluebird bio's Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting

Business Wire December 10, 2022

bluebird bio Sells Priority Review Voucher for $102 Million

Business Wire November 30, 2022

bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress

Business Wire November 7, 2022

bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference

Business Wire November 2, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

Business Wire September 16, 2022

Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall

Business Wire September 12, 2022

bluebird bio Announces September Investor Events

Business Wire August 29, 2022

bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

Business Wire August 17, 2022

bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

Business Wire August 17, 2022

bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress

Business Wire August 4, 2022

FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions

Business Wire June 10, 2022

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Business Wire June 9, 2022

bluebird bio stock trading halted today June 9th and tomorrow June 10th

Business Wire June 9, 2022

bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting

Business Wire June 7, 2022

bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress

Business Wire May 9, 2022

bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US

Business Wire April 5, 2022